Last reviewed · How we verify
Part A ABSK201 and Rifampicin
Part A ABSK201 and Rifampicin is a Small molecule drug developed by Abbisko Therapeutics Co, Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | Part A ABSK201 and Rifampicin |
|---|---|
| Sponsor | Abbisko Therapeutics Co, Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part A ABSK201 and Rifampicin CI brief — competitive landscape report
- Part A ABSK201 and Rifampicin updates RSS · CI watch RSS
- Abbisko Therapeutics Co, Ltd portfolio CI
Frequently asked questions about Part A ABSK201 and Rifampicin
What is Part A ABSK201 and Rifampicin?
Part A ABSK201 and Rifampicin is a Small molecule drug developed by Abbisko Therapeutics Co, Ltd.
Who makes Part A ABSK201 and Rifampicin?
Part A ABSK201 and Rifampicin is developed by Abbisko Therapeutics Co, Ltd (see full Abbisko Therapeutics Co, Ltd pipeline at /company/abbisko-therapeutics-co-ltd).
What development phase is Part A ABSK201 and Rifampicin in?
Part A ABSK201 and Rifampicin is in Phase 1.